Abstract
Variants in KMT2A, encoding the histone methyltransferase KMT2A, are a growing cause of intellectual disability (ID). Up to now, the majority of KMT2A variants are non-sense and frameshift variants causing a typical form of Wiedemann–Steiner syndrome. We studied KMT2A gene in a cohort of 200 patients with unexplained syndromic and non-syndromic ID and identified four novel variants, one splice and three missense variants, possibly deleterious. We used primary cells from the patients and molecular approaches to determine the deleterious effects of those variants on KMT2A expression and function. For the putative splice variant c.11322-1G>A, we showed that it led to only one nucleotide deletion and loss of the C-terminal part of the protein. For two studied KMT2A missense variants, c.3460C>T (p.(Arg1154Trp)) and c.8558T>G (p.(Met2853Arg)), located at the cysteine-rich CXXC domain and the transactivation domain of the protein, respectively, we found altered KMT2A target genes expression in patient’s fibroblasts compared to controls. Furthermore, we found a disturbed subcellular distribution of KMT2A for the c.3460C>T mutant. Taken together, our results demonstrated the deleterious impact of the splice variant and of the missense variants located at two different functional domains and suggested reduction of KMT2A function as the disease-causing mechanism.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
American Psychiatric Association, American Psychiatric Association. Task force on DSM-IV and American Psychiatric Association. Task force on nomenclature and statistics. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington, DC: American Psychiatric Association; American Psychiatric Press or American Psychiatric Publishing, 1994.
Srivastava AK, Schwartz CE. Intellectual disability and autism spectrum disorders: causal genes and molecular mechanisms. Neurosci Biobehav Rev 2014;46:161–74.
Brookes E, Shid Y. Diverse epigenetic mechanisms of human disease. Annu Rev Genet 2014;48:237–68.
Iwased S, Shid Y, Histone and DNA modifications in mental retardation. Prog Drug Res. 2011;67:147–73
Krumm N, O’Roak BJ, Shendure J, Eichler EE. A de novo convergence of autism genetics and molecular neuroscience. Trends Neurosci 2014;37:95–105.
Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693–705.
Jones WD, Dafou D, McEntagart M, et al.. De novo mutations in MLL cause Wiedemann-Steiner syndrome. Am J Hum Genet 2012;91:358–64.
Ng SB, Bigham AW, Buckingham KJ, et al.. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet 2010;42:790–3.
Grozeva D, Carss K, Spasic-Boskovic O, et al.. De novo loss-of-function mutations in SETD5, encoding a methyltransferase in a 3p25 microdeletion syndrome critical region, cause intellectual disability. Am J Hum Genet 2014;94:618–24.
Lederer D, Grisart B, Digilio MC, et al. Deletion of KDM6A, a histone demethylaseinteracting with MLL2, in three patients with Kabuki syndrome. Am J Hum Genet 2012;90:119–24.
Laumonnier F, Holbert S, Ronce N, et al.. Mutations in PHF8 are associated with X linked mental retardation and cleft lip/cleft palate. J Med Genet 2005;42:780–6.
Jensen LR, Amende M, Gurok U, et al.. Mutations in the JARID1C gene, which is involved in transcriptional regulation and chromatin remodeling, cause X-linked mental retardation. Am J Hum Genet 2005;76:227–36.
Cosgrove MS, Patel A. Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. FEBS J 2010;277:1832–42.
Zhang P, Bergamin E, Couture JF. The many facets of MLL1 regulation. Biopolymers 2013;99:136–45.
Hsieth JJ, Ernst R, Erdjument-Bromage H, Tempst P, Korsmeyer SJ, Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization. Mol Cell Biol. 2003;23:186–94
Stellacci E, Onesimo R, Bruselles A, et al.. Congenital immunodeficiency in an individual with Wiedemann-Steiner syndrome due to a novel missense mutation in KMT2A. Am J Med Genet A 2016;170:2389–93.
Calvel P, Kusz-Zamelczyk K, Makrythanasis P, et al.. A case of Wiedemann-Steiner syndrome associated with a 46,XY disorder of sexual development and gonadal dysgenesis. Sex Dev 2015;9:289–95.
Dunkerton S, Field M, Cho V, et al.. A de novo mutation in KMT2A (MLL) in monozygotic twins with Wiedemann-Steiner syndrome. Am J Med Genet A 2015;167A:2182–7.
Miyake N, Tsurusaki Y, Koshimizu E, et al.. Delineation of clinical features in Wiedemann-Steiner syndrome caused by KMT2A mutations. Clin Genet 2016;89:115–9.
Mendelsohn BA, Pronold M, Long R, Smaoui N, Slavotinek AM, Advanced bone age in a girl with Wiedemann-Steiner syndrome and an exonic deletion in KMT2A (MLL). Am J Med Genet A. 2014;164A:2079–83
Martínez F, Caro-Llopis A, Roselló M, et al. High diagnostic yield of syndromic intellectual disability by targeted next-generation sequencing. J Med Genet 2017; doi: https://doi.org/10.1136/jmedgenet-2016-103964. PubMed PMID: 27620904.
Strom SP, Lozano R, Lee H, et al.. De Novo variants in the KMT2A (MLL) gene causing atypical Wiedemann-Steiner syndrome in two unrelated individuals identified by clinical exome sequencing. BMC Med Genet 2014;15:49.
Ko JM, Cho JS, Yoo Y, Seo J, Choi M, Chae JH, Lee HR, Cho TJ, Wiedemann-Steiner syndrome with 2 novel KMT2A mutations. J Child Neurol. 2017;32:237–42
Sun Y, Hu G, Liu H, et al.. Further delineation of the phenotype of truncating KMT2A mutations: the extended Wiedemann-Steiner syndrome. Am J Med Genet A 2017;173:510–4.
Helbig KL, Farwell Hagman KD, Shinde DN, et al.. Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy. Genet Med 2016;18:898–905.
Aggarwal A, Rodriguez-Buritica DF, Northrup H. Wiedemann-Steiner syndrome: novel pathogenic variant and review of literature. Eur J Med Genet 2017;60:285–8.
Yano T, Nakamura T, Blechman J, et al.. Nuclear punctate distribution of MLL-1 is conferred by distinct elements at the N terminus of the protein. Proc Natl Acad Sci USA 1997;94:7286–91.
Wang P, Lin C, Smith ER, et al.. Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol Cell Biol 2009;29:6074–85.
Zeisig BB, Milne T, García-Cuéllar MP, et al.. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 2004;24:617–28.
Bina M, Wyss P, Novorolsky E, et al.. Discovery of MLL1 binding units, their localization to CpG Islands, and their potential function in mitotic chromatin. BMC Genom 2013;28:927.
Milne TA, Hughes CM, Lloyd R, et al.. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci USA 2005;18:749–54.
Koenig R, Meinecke P, Kuechler A, Schäfer D, Müller D. Wiedemann-Steiner syndrome: three further cases. Am J Med Genet A 2010;152A:2372–5.
Jakovcevski M, Ruan H, Shen EY, et al.. Neuronal Kmt2a/Mll1 histone methyltransferase is essential for prefrontal synaptic plasticity and working memory. J Neurosci 2015;35:5097–108.
Huang YC, Shih HY, Lin SJ, et al.. The epigenetic factor Kmt2a/Mll1 regulates neural progenitor proliferation and neuronal and glial differentiation. Dev Neurobiol 2015;75:452–62.
Allen MD, Grummitt CG, Hilcenko C, et al.. Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase. EMBO J 2006;25:4503–12.
Whitman SP, Liu S, Vukosavljevic T, et al.. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood 2005;106:345–52.
Trivedi CM, Patel RC, Patel CV, Differential regulation of HOXA9 expression by nuclear factor kappa B (NF-kappaB) and HOXA9. Gene. 2008;408:187–95
Inturi R, Wäneskog M, Vlachakis D, et al.. A splice variant of the human phosphohistidine phosphatase 1 (PHPT1) is degraded by the proteasome. Int J Biochem Cell Biol 2014;5:69–75.
Acknowledgements
The authors thank the families for their participation to the study. They want also to thank Thierry Gaillon from the Henri Mondor Hospital molecular diagnostic lab for the technical support, and Patrick Nusbaum and Arnaud Hubas for providing primary cultures of fibroblasts. I.G. received support from La Fondation Jérôme Lejeune and from GIS - Institut des Maladies Rares.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Lebrun, N., Giurgea, I., Goldenberg, A. et al. Molecular and cellular issues of KMT2A variants involved in Wiedemann-Steiner syndrome. Eur J Hum Genet 26, 107–116 (2018). https://doi.org/10.1038/s41431-017-0033-y
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41431-017-0033-y
This article is cited by
-
Diagnosis and recombinant human growth hormone treatment of Wiedemann–Steiner syndrome: discovery of novel KMT2A variants and review of existing literature
BMC Pediatrics (2025)
-
Wiedemann-Steiner syndrome: description of genetic profiles and clinical phenotypes of 10 Korean pediatric patients
BMC Medical Genomics (2025)
-
KMT2A-CBL fusion gene in the first reported case of T-cell acute lymphoblastic leukemia associated with Wiedemann-Steiner syndrome
International Journal of Hematology (2025)
-
Clinical and molecular results in 15 Turkish patients with Wiedemann-Steiner syndrome: identification of eight novel KMT2A variants and a case of dual molecular diagnosis in the CSNK2A1
European Journal of Pediatrics (2025)
-
Single-cell analysis reveals the spatial-temporal expression of genes associated with esophageal malformations
Scientific Reports (2024)
